Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Zyprexa-Prozac Med Approved For Depression

Posted by Jane Akre
Monday, March 23, 2009 10:17 AM EST
Category: Major Medical, Protecting Your Family, In The Workplace
Tags: Antipsychotics, Depression, Bipolar Disease, Zyprexa, Prozac, FDA and Prescription Drugs

New drug by Lilly to treat depression approved. 



IMAGE SOURCE: iStockphoto/ depressed teen


It promises to be another blockbuster for Eli Lilly and Co.

The Food and Drug Administration (FDA) has approved the company’s new drug, Symbyax, for treatment-resistant bipolar depression.  

The new drug combines the active ingredients in Zyprexa and Prozac, giving Lilly a way around the patent expiration of Prozac. 

This is the first drug approved by the FDA for depression that has not successfully been treated in at least two previous attempts.  

Symbyax will carry a warning about weight gain, hyperglycemia (high blood sugar) which can turn into diabetes, and hyperlipidemia (elevated lipids in the bloodstream including cholesterol).

While Prozac or fluoxetine lost its patent protection and blockbuster profits for Lilly, Zyprexa or olanzapine, has had a series of bad press, mainly because of its link to diabetes. It has also faced competition from generics overseas.

Eli Lilly had to pay the federal government more than $1.4 billion to settle an off-label marketing scheme for its prescription drug, Zyprexa.

The settlement was the largest amount paid by a single defendant in the history of the U.S. Department of Justice.   

IB member attorney Stephen Sheller filed the first complaint in February 2003.  The allegations originated from six former Lilly drug marketing representatives who became whistleblowers. 

“They reported what they felt was very wrong and tried to do it first within the company boundaries, but no one was interested in hearing that,” says Jamie Sheller of Sheller P.C.

And patients should be aware of the latest findings in the New England Journal of Medicine.  

Patients taking a newer group of atypical antipsychotics are twice as likely to suffer sudden cardiac failure and death as nonusers, the study finds.   The convention wisdom was the newer antipsychotics were safer than the older ones.  

Atypicals include AstraZeneca’s Seroquel, Eli Lilly’s Zyprexa, Johnson & Johnson’s Risperdal and Novartis’s Clozaril. 

An accompanying editorial says we should reduce the use of atypical drugs in children and elderly patients.   #

1 Comment

Posted by Daniel Haszard
Monday, March 23, 2009 11:19 AM EST

Zyprexa matrix reloaded?
Lilly has a heavy indebtedness with Zyprexa damage claims that are still outstanding.
Investors take note.


Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes